OVARIAN CANCER

This early-phase study tests whether a new treatment, called iC9-CAR.B7-H3 T cells, is safe for people with ovarian cancer that came back after standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. About …

This early-stage study is testing a new drug, AOH1996, in adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and understand side effects. The drug works by blocking certai…

This study tests whether the drug belzutifan can shrink or control tumors in people with recurrent clear cell cancers of the ovary, uterus, cervix, vagina, or vulva. About 32 participants will receive the drug and be monitored for tumor response and side effects. The goal is to s…

This study tests whether adding an experimental drug (IMNN-001) to standard chemotherapy and bevacizumab can better eliminate leftover cancer in people with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 30 participants will be randomly assigned to …

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with advanced ovarian cancer live longer. It includes 520 adults with stage 3 or 4 ovarian cancer who have already received three rounds of chemo. Participants are randomly a…

This early-phase study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug is working against the cancer.

This study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or slow tumor growth. Participants will receive the drug alone…

This study tests an experimental drug called INCB123667 in people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. About 160 participants will receive the drug to see if it can shrink tumors or slow …

This early-stage study tests a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurab…

This early-stage study tests a new experimental drug (NMS-03305293) combined with standard chemotherapy (topotecan) in 24 people whose ovarian cancer has returned after prior treatments. The main goal is to find a safe dose and check for side effects. Researchers will also watch …

This early-phase study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 272 …

This program gives people with certain solid tumors or blood cancers access to an experimental drug called AVM0703. It is for patients in the US whose doctor requests it. So far, 37 patients have received the drug, and side effects have been mostly mild, like itching during infus…

This early-phase trial tests OPB-101, a one-time treatment made from a patient's own immune cells, for ovarian cancer that no longer responds to platinum chemotherapy. The cells are modified in a lab to target a protein called mesothelin on cancer cells and produce a designed IL-…

This study is testing a new robotic surgery system (Medtronic Hugo™) to see if it is safe and works well for hysterectomy. About 70 adult women with conditions like fibroids, endometriosis, or certain cancers will take part. The main goal is to see if the surgery can be completed…

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. About 319 participants will receive the drug to…

This study is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific marker called folate receptor alpha (FRα). Participants will receive a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) before…

This study tests whether adding bevacizumab to niraparib after standard chemotherapy works better than niraparib alone for women with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 970 participants will be randomly assigned to one of two treatment g…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs (gemcitabine or irinotecan). About 442 adults will take p…

This study is for people with ovarian, fallopian tube, or peritoneal cancer that has returned after treatment with PARP inhibitors. The trial compares a targeted drug called trastuzumab deruxtecan (T-DXd) against standard chemotherapy. T-DXd targets a protein called HER2 found on…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study tests a new drug called CUSP06 for people with ovarian cancer or other solid tumors that have stopped responding to standard treatments. The drug works like a guided missile, targeting a protein on cancer cells to deliver a powerful toxin directly. The main goals are t…

This early-stage study tests a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to other treatments. The main goals are to check if the drug is safe and to find the best dose. About 282 participants will take part, …

This early-phase study tests whether adding lurbinectedin to two standard chemotherapy drugs (paclitaxel and bevacizumab) can better control platinum-resistant ovarian cancer. About 34 adults with advanced ovarian, fallopian tube, or peritoneal cancer will receive the combination…

This early-stage trial tests an experimental drug called IVX037, injected directly into tumors, for people with advanced colorectal, gastric, or ovarian cancers that have stopped responding to standard treatments. The study has two parts: first, testing IVX037 alone to find a saf…

This study tests a drug called valemetostat in people with advanced solid tumors that have certain gene changes (like SMARCB1 or ARID1A). The drug aims to reactivate protective genes to slow or stop cancer growth. About 900 adults will take the drug daily for up to 2 years, with …

This early-stage study tests an experimental drug called XNW28012 in 350 adults with advanced solid tumors (including pancreatic, ovarian, and cervical cancers) that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. P…

This early-phase study tests a new drug (DT2216) combined with standard chemotherapy (paclitaxel) in 30 people with ovarian cancer that has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel, and t…

This study tests whether adding a targeted drug (olaparib) to heated chemotherapy during surgery can safely treat advanced ovarian cancer. About 55 adults with stage III or certain stage IV ovarian cancer will take part. The goal is to find the best dose and check for side effect…

This study tests whether a daily pill called isoquercetin (a natural compound found in fruits) can reduce blood markers linked to dangerous clots in people with ovarian cancer. About 90 participants receiving first-line chemotherapy will take either isoquercetin or a placebo for …

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and then infu…

This study tests a personalized cancer vaccine made from patients' own tumor cells grown in a lab. The cells are modified to trigger a stronger immune response, then killed and injected back into the patient. The goal is to help the immune system fight metastatic cancers like mel…

This study tests a three-drug chemotherapy and immunotherapy combination given before surgery, followed by maintenance therapy after surgery, in 20 people with newly diagnosed stage III or IV ovarian cancer. The goal is to see if this approach delays cancer progression. Participa…

This study tests a new drug, TER-2013, in people with advanced solid tumors that have certain genetic changes (AKT/PI3K/PTEN pathway). The goal is to see if the drug is safe and can shrink or control the cancer. About 205 participants with cancers like breast, endometrial, ovaria…

This study tests whether two drugs, hydroxychloroquine and nelfinavir, can help keep high-grade serous ovarian cancer from returning when given alongside standard maintenance therapy. About 38 women whose cancer responded to platinum chemotherapy will take these drugs for up to 6…

This study tests a technique called acute normovolemic hemodilution (ANH) during surgery for advanced ovarian cancer. The goal is to see if ANH reduces the need for blood transfusions. About 86 adults with stage IIIC or IV ovarian cancer will take part. Before surgery, they are r…

This study tests a new drug called INCB123667 against standard chemotherapy in people with a type of ovarian cancer that no longer responds to platinum-based treatments. The trial is for those whose tumors have high levels of a protein called cyclin E1. About 466 participants wil…

This study looks at whether having surgery after chemotherapy can help people with recurrent ovarian cancer live longer without the disease getting worse. It involves 80 participants whose cancer returned and who responded to chemo. The goal is to see if adding surgery improves o…

This study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The drug works by blocking a protein (PARG) that cancer cells need to repair themselves. The main goal…

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will join to see if the combination helps slow cancer growth. The goal is to control the disease, not cur…

This early-phase study tests a new experimental drug (SYN818) combined with the approved cancer drug olaparib in adults with advanced solid tumors, including ovarian and breast cancers linked to BRCA gene changes. The main goals are to find the safest dose and check for side effe…

This study tests a new drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, pancreatic, skin cancer, or glioblastoma. The main goal is to check if the drug is safe and to find the right dose. About 80 adults will take part in two phases, s…

This study tests if surgery followed by heated chemotherapy directly in the abdomen can help women whose mucinous ovarian cancer has come back. About 30 participants will receive this combined treatment. The goal is to see how long they live without the cancer growing again.

This study is testing a new drug called Dato-DXd, either alone or with other cancer drugs, in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gastric, prost…

This early-phase study tests a new drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe, tolerable, and can shrink tumors. Participants must have tried at least two prior standard treatments.

This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent dir…

This early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The main goals are to fin…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find the safest dose and c…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive cancers that have spread and no longer respond to other treatments. About 100 people with various cancer types will be followed in real-world clinics to see if their tumors shrink and how long…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This study tests a new experimental drug, ACE-86225106, in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors. About 298 participants will receiv…

This study tests a new treatment called CD70-targeted CAR-T cells for people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a specifi…

This study is for women with advanced, high-grade ovarian cancer that has been fully removed by surgery. It compares two treatment plans: 3 cycles of chemotherapy followed by the maintenance drug niraparib versus 6 cycles of chemotherapy followed by niraparib. The goal is to see …

This study tests a new method called PIPAC, which delivers chemotherapy as a spray directly into the abdomen, for people with advanced ovarian cancer. The goal is to see if it works better than standard chemotherapy before surgery. About 60 people with high-grade ovarian cancer t…

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can slow tumor…

This study tests a new drug called HLX43 in people with advanced cervical or ovarian cancer that came back or spread after standard first treatment. The drug targets a protein on cancer cells to deliver a toxin directly. About 190 adults will receive the drug to see if it shrinks…

This study tests whether adding the experimental drug Rina-S to standard therapy helps keep ovarian cancer from coming back. About 528 people with platinum-sensitive ovarian cancer will receive either Rina-S alone, Rina-S plus bevacizumab, bevacizumab alone, or monitoring only. T…

This study tests new immunotherapy drug combinations in women with a tough-to-treat type of ovarian cancer that no longer responds to platinum chemotherapy. About 60 participants will receive different immunotherapy regimens to see which works best. The goal is to find promising …

This study tests whether a special camera that shows blood flow in the bowel during surgery can lower the risk of dangerous leaks after ovarian cancer surgery. About 310 women having surgery for ovarian cancer will take part. The camera uses a glowing dye to help surgeons see pro…

This study tests an experimental drug called mirvetuximab soravtansine (MIRV) combined with either bevacizumab or carboplatin in people with a specific type of ovarian cancer. About 320 participants will receive different doses to find the safest and most effective treatment. The…

This study tests a new treatment for people with cancers that have a specific marker called CD70, including pancreatic, kidney, breast, melanoma, and ovarian cancers. Researchers take a person's white blood cells, modify them in the lab to recognize and attack CD70, and then give…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have MAPK pathway mutations (like KRAS or BRAF) and who have not responded to or exhausted other treatments. The goal is to offer compassionate access to this medication, either alo…

This study tests a new drug called HS-20089 against standard chemotherapy in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 participants will be randomly assigned to receive either HS-20089 or …

This early-phase trial tests a new treatment for adults with ovarian cancer that has returned and is no longer responding to standard chemotherapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main…

This study tests a new drug called BI-1808, alone or with another drug (pembrolizumab), in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best…

This study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after their first round of treatment. Niraparib works by stopping cancer cells from repairing themselves, which may slow or stop tumor growth. Researchers will …

This study tests a new drug (SHR-A1811) combined with standard chemotherapy for women whose ovarian cancer has come back after initial treatment. About 150 participants will receive the combination to see if it is safe and works better than current options. The goal is to control…

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with recurrent ovarian cancer live longer without their cancer growing. About 770 adults whose cancer responded to platinum-based chemotherapy will receive either…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific TP53 Y220C mutation. The trial has two parts: first, finding the safest dose, and then seeing how well the drug works alone or with another drug (pembrol…

This study tests a new drug called AZD8205, alone or with other cancer treatments, for people with advanced solid tumors like breast, ovarian, or lung cancer that have spread. About 460 adults whose cancer has not responded to standard care will take part. The main goal is to che…

This early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…

This study tests a single injection of Radspherin, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. The goal is to see if it can delay cancer growth …

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, as maintenance treatment for people with advanced ovarian cancer that has not responded well to standard chemotherapy. The goal is to see if these treatments can keep the …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses a patient's own immune cells, which are …

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults with se…

This study is for people with advanced ovarian cancer that has a BRCA gene mutation. It compares two different forms of the drug olaparib to see if they work the same way in the body. About 40 participants will take both versions at different times, and researchers will measure d…

This study tests two drugs, fuzuloparib and apatinib, given before surgery to shrink tumors in people with advanced ovarian cancer that has specific gene changes (HRD-positive). The goal is to make surgery more complete and reduce the need for chemotherapy. About 48 participants …

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. About 220 participant…

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…

This early-stage trial tests a new treatment called IDOV-Immune, a virus designed to infect and destroy cancer cells while also boosting the immune system. It is for adults with advanced solid tumors (like colorectal, lung, or breast cancer) that have not responded to standard tr…

This study tests a new drug called LY4052031 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find safe doses and see if the drug can shrink tumors. About 420 participants will take part over up to 4 years.

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: one with niraparib alone and another with niraparib plus bevacizumab. The goal is to see which combination better delays cancer from return…

This early study tests a new treatment called SY001 for people with advanced ovarian or pancreatic cancer that has not responded to at least one prior therapy. SY001 uses specially engineered immune cells (CAR-macrophages) to target a protein called mesothelin found on cancer cel…

This study tests an experimental drug, REGN5668, alone or with other immune-boosting drugs, in people with ovarian, fallopian tube, peritoneal, or endometrial cancers that have not responded to standard treatment. The goal is to find the safest dose and see if the combination can…

This study is for people under 30 with disorders of sex development who are at high risk of infertility or ovarian cancer. Researchers will remove and freeze ovarian tissue before it is surgically removed for medical reasons. The goal is to see if this tissue can later be used to…

This study tests an experimental drug called AZD5335, alone or with other cancer treatments, in people with advanced ovarian, lung, or endometrial cancers that have not responded to standard therapy. The main goals are to check safety and find the right dose. About 506 participan…

This early-stage trial tests whether a new type of immune cell therapy is safe for people with ovarian cancer that has come back. The treatment uses a patient's own T cells, which are modified in a lab to recognize and attack cancer cells that have a specific marker (FSHR). Up to…

This study tests a new treatment called EBNK-001, which uses donor natural killer (NK) cells to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive NK cells along with chemot…

This study tests a new treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen by analyzing a tumor sample or a blood test. The study includes adults aged 18-75 with advanced solid tumors that have not respond…

This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with a hard-to-treat type of ovarian cancer (platinum-resistant). About 33 adults with high-grade serous ovarian cancer that has stopped responding to platinum-based chemo…

This early-stage study tests a one-time treatment called SynKIR-110, made from a patient's own immune cells modified to attack cancer cells that have a protein called mesothelin. It is for adults with advanced ovarian cancer, bile duct cancer, or mesothelioma that has come back a…

This study tests whether adding mirvetuximab soravtansine to standard maintenance therapy (bevacizumab) can delay cancer regrowth in people with a specific type of ovarian, fallopian tube, or peritoneal cancer. Participants must have cancer that responded to initial platinum-base…

This early-stage study tests a new drug, QXL138AM, for safety in about 100 people with advanced solid tumors (like ovarian, pancreatic, lung, or breast cancer) or multiple myeloma. Participants must have tried other treatments without success. The study will find the right dose a…

This study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people whose ovarian or endometrial cancer has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well it shrinks tumors. About 54 particip…

This study tests a new treatment called THEO-260, a virus designed to infect and kill cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. About 44 participants will receive different doses of the virus through an IV to find the s…

This study tests a new drug called TUB-040 in people with advanced ovarian cancer or a type of lung cancer that has stopped responding to standard treatments. The drug works like a guided missile, delivering a cancer-killing agent directly to tumor cells that have a specific mark…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The treatment uses the patient's own immune cells, modified to target cancer cells while sparing healthy ones. The s…

This study tests a new drug combination (distamab vedotin plus carboplatin) for people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combo works better and causes fewer side effects than standard chemotherapy. About 20 participan…

This study tests whether combining two targeted drugs (a PARP inhibitor and an angiogenesis inhibitor) as maintenance therapy can delay cancer return in people with advanced ovarian, fallopian-tube, or primary peritoneal cancer that has a specific DNA repair defect (HRD). About 1…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This early study is testing an experimental oral drug called ATX-295 in about 90 people with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-phase study tests whether a new drug called NRM-823 is safe and can help people with advanced solid tumors that have not responded to other treatments. About 150 adults with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 alone or with…

This study tests an experimental drug called COM701 in 60 people with ovarian cancer that came back after initial treatment. The goal is to see if COM701, given as maintenance therapy, can delay the cancer from growing again. Participants receive the drug or a placebo every three…

This early-phase study tests a new daily pill, NKT3964, in adults with advanced solid tumors (like ovarian, endometrial, breast, lung, or stomach cancer) that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose, whi…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, ovarian, or lung cancer) that haven't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors, either alone or combine…

This early-stage study tests an experimental oral drug, NKT5097, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and understand side effects. About 205 participants with breast, ovarian, endometrial, or othe…

This study is for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. It tests a new drug called LBL-024 combined with paclitaxel (a standard chemo drug) to see if the combination can shrink tumors and delay cancer growth. About 110 adults will …

This early-phase study tests a new drug, CLSP-1025, designed to attack cancer cells that have a specific change in the p53 gene (called R175H). The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have this mutation and have not respon…

This study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK cells) given directly into the abdomen. It is for people with ovarian, mesonephric, or pancreatic cancer that has stopped responding to standard treatments. The main goal is to find a safe dose…

This early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This early-stage study tests a new personalized immunotherapy called Innocell in 8 women with recurrent epithelial ovarian cancer. The treatment is made from each patient's own tumor tissue and aims to train the immune system to fight the cancer. The main goals are to see if the …

This early-stage trial tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The study will give different doses directly into the abdomen to find the safest dose an…

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer. About 500 newly diagnosed adults will receive either chemo alone or chemo plus IMNN-001, g…

This study tests a new treatment that delivers a powerful, short-range radioactive particle directly to cancer cells that have a protein called FAP on their surface. The therapy is given in two steps: first a low-dose imaging version to see if the tumor takes up the drug, then a …

This study tests whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 women will take niraparib pills for as long as they help, and researchers will track how long the cancer stays away.…

This early-phase study tests the safety and best dose of a new drug called BL0175 in postmenopausal women with advanced hormone receptor-positive breast, ovarian, or endometrial cancer that has spread or cannot be removed by surgery. About 9 participants will receive multiple dos…

This early-stage study is testing a new drug called ABBV-901 for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. Researchers will give the drug alone and in combination with an existing cancer therapy (bevacizumab) to about 207 pa…

This study is testing a new treatment for advanced ovarian cancer. Doctors take a patient's own immune cells (T-cells), modify them in a lab to better target cancer, and then infuse them back into the patient. The main goals are to see if this cell therapy is safe and if it can h…

This study is testing whether a combination of three existing drugs can help control high-grade ovarian cancer that remains in small amounts after a patient's first round of treatment. It will involve about 20 adult women with this specific type of cancer. The main goals are to s…

This trial is for people with advanced ovarian cancer who are not responding well to their initial chemotherapy. It will test if switching to a more frequent, weekly chemotherapy schedule is better than continuing the standard three-week schedule. The goal is to see if the weekly…

This study is testing whether adding a newer targeted drug (trastuzumab deruxtecan) to standard maintenance therapy (bevacizumab) works better than the standard therapy alone to keep advanced ovarian cancer from returning. The trial will enroll 582 adults with newly diagnosed, ad…

This study is testing a new experimental drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to find and deliver radiation directly to cancer cells. The main goals are to f…

This study is testing whether a combination of three drugs can help control recurrent ovarian cancer. It will involve about 20 adults whose cancer has returned after initial treatment. The main goals are to see if the treatment shrinks tumors and to understand what side effects p…

This is an early-stage study testing a new drug called MT-4561 in people with various advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it might hel…

This study is testing a new type of PET scan that targets a protein called Trop2, found on many solid tumors. The goal is to see if this scan can find and stage cancers like lung, bladder, and prostate more accurately than current methods. About 400 adults with confirmed or suspe…

This study is testing whether changes in platelet RNA can help doctors diagnose ovarian cancer earlier and more accurately. Researchers will collect blood samples from 245 women—those with an ovarian mass and healthy volunteers—to see if this new approach works. If successful, it…

This study looks at whether the things people buy at stores—like painkillers or indigestion remedies—could be early warning signs of cancer. Many cancers cause vague symptoms that people treat with over-the-counter products before seeing a doctor. Researchers will compare the sho…

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery. Surgeons can then see and remove tumors they might otherwise miss. About 170 women with suspected or recurrent ovarian cancer will take part. The study lasts about 2 weeks and aims to impr…

This study tests whether a new radioactive tracer called 18F-FAPI-74 can find certain cancers as well or better than the standard FDG tracer on PET scans. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both trace…

This study is testing whether combining a standard CA125 blood test with other blood markers can help detect ovarian cancer earlier in women who are at low risk. Researchers will track changes in these markers over time in 8,000 postmenopausal women aged 50-75. The goal is to imp…

This study aims to develop a test that can detect endometrial, ovarian, and cervical cancers by looking for specific DNA markers in vaginal fluid or blood. Researchers will collect samples from over 3,000 women to see how accurate the test is. The goal is to create a simple, non-…

This study is testing a new blood test that uses laser technology and artificial intelligence to find early signs of breast, colon, pancreatic, ovarian, and lung cancers. Researchers will collect blood samples from 1,400 people aged 45 and older who are suspected of having one of…

This study is testing a new platform that uses advanced testing to better understand different types of cancer, including leukemia, myeloma, and solid tumors. The goal is to see if this platform can change the recommended treatment for patients, making it more personalized. About…

This study explores whether a tampon can collect DNA samples to detect endometrial and ovarian cancer early. Researchers will compare tampon samples with tissue from surgery in 1,500 women. The goal is to develop a simple, non-invasive screening tool that could catch these cancer…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will check if the test can find cancer early, tell which type it is, and detect any remaining cancer after treatment or a relapse before …

This study is testing whether yearly vaginal ultrasound can improve the detection of ovarian cancer in women at intermediate to high risk. Researchers want to see if this screening method can reduce false alarms while still catching real cancers early. About 65,000 women from Ken…

This study tests a new two-step surgery for women with high genetic risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, they first remove only the tubes, then remove the ovaries years later. The goal is to see if this approach is as safe and effe…

This study follows women with genetic mutations (like BRCA1/2) that raise their risk for ovarian cancer. Participants choose either preventive surgery (removing fallopian tubes now, ovaries later, or both) or close monitoring. Researchers track cancer rates, ovarian function, and…

This study looks at whether removing the fallopian tubes first and delaying the removal of the ovaries is as safe as removing both at once for preventing ovarian cancer. It involves 100 premenopausal women with BRCA or other high-risk gene mutations. Participants choose their pre…

This study tests whether drinking tart cherry juice can prevent nerve pain caused by the chemotherapy drug paclitaxel in people with breast or ovarian cancer. About 86 participants will be randomly assigned to take either a high or low dose of the juice during their 12-week chemo…

This study offers a yoga therapy program to women with ovarian cancer who are getting chemotherapy before surgery. The goal is to see if the program is practical and helps improve quality of life. About 40 participants will take part online from home.

This study looks at whether a program of exercise and nutrition, called prehabilitation, can help elderly patients (65 and older) with advanced ovarian or pancreatic cancer stay strong while they receive chemotherapy before surgery. About 22 participants will follow the program t…

This study tests a tool called CASI that helps ovarian cancer patients, their caregivers, and doctors set a shared plan for each doctor visit. The goal is to make sure everyone talks about what matters most to the patient. About 112 people with advanced ovarian cancer will take p…

This study tests a short counseling program called CALM for women with advanced ovarian cancer. The goal is to see if it's helpful and practical to offer at the time of diagnosis or recurrence. Participants will fill out questionnaires and may attend 3-6 therapy sessions.

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely reduce diarrhea and colon inflammation caused by immune-checkpoint inhibitors in people with genitourinary and other cancers. About 40 participants will receive FMT and be monitored for side ef…

This study tests whether a 16-week virtual exercise program (aerobic and resistance training) can help patients with ovarian or endometrial cancer maintain leg function and reduce numbness or tingling in hands and feet caused by chemotherapy. Thirty patients who have had surgery …

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce the intense fear of cancer returning in women who have finished treatment for early-stage breast or ovarian cancer. Twenty women in remission will…

This study tests a supportive telehealth program called REVITALIZE to see if it can lessen how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitors. About 240 participants will either receive the REVITALIZE program or educ…

This study looks at whether a program of exercise, nutrition advice, and mental support before surgery (called prehabilitation) can help people with ovarian or endometrial cancer recover faster and feel better. About 64 patients will be randomly assigned to either standard care o…

This study tests a program called PROADAPT for women aged 70+ (or 60+ with health issues) who have advanced ovarian cancer and need surgery. The program includes nutrition support, physical therapy, and education before surgery, plus extra care during and after the hospital stay.…

This early-phase study is testing whether adding aspirin to standard chemotherapy can reduce immune-suppressing cells inside ovarian, fallopian tube, or peritoneal tumors. About 100 women will take aspirin alongside their chemo before surgery. The goal is to see if this simple, l…

This study is testing whether a virtual mind-body program called Integrative Medicine at Home (IM@Home) can help people with head and neck, thoracic, gynecologic, or other cancers feel less tired and have a better quality of life while receiving treatments like chemotherapy or ra…

This study is testing whether the drug riluzole can prevent or reduce thinking and memory problems (often called 'chemo brain') in cancer patients receiving chemotherapy. It will enroll 24 adults with various cancers who are scheduled to receive specific types of chemotherapy. Pa…

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer, along with their medical information. The samples will be stored and used by researchers to develop better ways to detect, monitor, and understand cancer over time…

This study is for women with advanced or metastatic gynecologic cancers (cervical, endometrial, ovarian, or vulvar) who are receiving immunotherapy. Researchers want to see if changes in a blood marker called CRP can help predict how well the treatment works and how long patients…

This study is developing a simple blood test that uses artificial intelligence to find cancer early and check if treatments are working. Researchers will analyze blood samples from 6,000 adults with or without cancer to identify unique signals in platelets and immune cells. The g…

This study aims to identify women at risk for hereditary breast, ovarian, and colorectal cancers who may not have easy access to genetic testing. Using mobile mammography units, researchers will offer genetic screening and counseling to 1,000 underserved women in Texas during the…

This study aims to understand how ovarian cancer weakens the immune system, especially in the bone marrow and blood. Researchers will compare immune cells from 90 women with ovarian cancer to those without cancer. The goal is to find ways to retrain immune cells to fight the tumo…

This study collects blood and leftover tissue from 9,600 people with various solid tumors, such as breast, lung, and pancreatic cancer. The samples help researchers develop better tests to detect cancer recurrence and monitor treatment response. Participants provide samples and m…

This study aims to collect information from 25 adults with breast, lung, ovarian, multiple myeloma, or acute myelogenous leukemia. Participants will use a phone, tablet, or computer to complete weekly surveys about their symptoms for at least 12 weeks. The goal is to build a data…

This study looks at whether a polygenic risk score (PRS) can help predict the chance of developing ovarian cancer. Researchers will compare the PRS of 1300 Italian women with and without ovarian cancer. Participants will fill out a questionnaire and give a blood sample for geneti…

This study aims to find biological markers in tumor, blood, and other samples from 350 ovarian cancer patients. Researchers will track how these markers change with treatment and relate to outcomes like progression-free survival. The goal is to better understand why some cancers …

This study collects blood or cheek swab samples from people with cancer who are being treated at the National Cancer Institute. Researchers want to analyze genetic differences that may affect how the body processes cancer treatments and influence side effects. The goal is to bett…

This study looks at whether keeping the left colic artery intact during surgery for colorectal or ovarian cancer helps maintain better blood flow to the colon. About 50 adults scheduled for left-sided colon, rectal, or ovarian cancer surgery will participate. Researchers will mea…

This study looks at 88 women with advanced ovarian cancer to compare two tests that check for a DNA repair problem called HRD. The goal is to see if these tests can predict which patients will respond well to platinum chemotherapy and might benefit from a PARP inhibitor. Particip…

This study is building a platform to better understand who is at risk for developing or having a cancer recurrence. Researchers will collect blood and tissue samples from 850 people with breast, colon, ovarian, melanoma, or lung cancer to look for genetic markers and other biolog…

This study is testing whether an artificial intelligence tool can help connect cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to ma…

This study aims to collect and analyze genetic information from 25,000 adults who either have cancer or are at risk of developing it. Researchers will look at tumor DNA and other health records to better understand what drives different cancers. The goal is to find new ways to de…

This study will collect tumor and blood samples from 1100 people with various cancers (like head and neck, ovarian, and lung cancer) to measure how active certain immune cells (T cells) are. The goal is to learn more about why some cancers trigger a stronger immune response than …

This study aims to collect and analyze genetic information from 300 Taiwanese women with ovarian cancer. Researchers will look at tumor tissue and medical records to find gene changes linked to treatment resistance or better outcomes. The goal is to build a database that can guid…

This study is a registry that collects information from about 1,975 people with advanced ovarian or endometrial cancer in Germany. Researchers will track what treatments patients actually receive, how their disease progresses, and how they feel over time. The goal is to better un…

This study looks at how the antifungal drug itraconazole changes the way the body processes a new cancer drug (AZD5335) in people with ovarian, primary peritoneal, or fallopian tube cancer. About 24 participants will receive both drugs in a fixed order to measure drug levels in t…

This study is looking for genetic targets in ovarian cancer, especially a common type called high-grade serous ovarian carcinoma. Researchers will study tissue samples from 180 women to find genes that might help diagnose or treat the disease. The goal is to better understand the…

This study is for people with advanced ovarian cancer whose disease has stopped responding to platinum-based chemotherapy. Researchers will use a sample of your stored tumor tissue to test whether a special method (called DRP) can predict if you might benefit from certain investi…

This study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand which cancers lose a specific marker (HLA) and to store participants' own T cells for possible future CAR T-cell ther…

This study is observing 1,000 women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer to see how their genetic makeup (BRCA and HRD status) relates to their standard treatment outcomes. Participants receive usual care, and researchers track surgery result…

This study aims to create and test a simple, Spanish-language tool that helps patients with ovarian cancer make informed decisions about their ongoing (maintenance) therapy. Researchers will work with 70 Spanish-speaking patients and their doctors to see if the tool reduces regre…

This study aims to see if lab-grown tumor models can predict how well heated chemotherapy (HIPEC) works during surgery for cancers that have spread to the abdomen. About 60 adults whose tumors cannot be fully removed safely will take part. Researchers will compare tumor responses…

This study observes 750 women with advanced ovarian cancer in Germany who are starting first-line platinum-based chemotherapy. It collects information on how patients are treated, their experiences, and outcomes like cancer progression. The goal is to learn more about the effecti…

This study looks at how ovarian cancer is treated in Brazil by collecting information from 250 patients. Researchers will review medical records and follow patients over time to see what treatments are used and what the outcomes are. The goal is to find ways to improve care and s…

This study is creating and improving educational materials about genetic testing for people with breast, ovarian, prostate, pancreatic, or colorectal cancer. Researchers will interview 445 patients from diverse cultural and language backgrounds to get their feedback. The goal is …

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find ovarian cancer recurrence earlier than current methods like CT scans or CA-125 blood tests. About 30 women with advanced ovarian cancer will give blood samples over time during their follow-up. I…

This study looks at how chemotherapy given before surgery (neoadjuvant chemotherapy) affects thinking and memory in women with advanced ovarian cancer. Researchers will test 18 participants using simple mental tasks over about 10 months. The goal is to better understand the cogni…

This study looks at how well patients aged 70 and older with advanced ovarian cancer tolerate PARP inhibitors, a type of targeted cancer drug. Researchers will track side effects and dose adjustments in 50 participants over time. The goal is to identify factors that help doctors …

This study looks at whether a family history screening program can help more women in rural public health clinics get tested for genetic risks linked to breast and ovarian cancer. About 3,200 women will take part to see if the program increases screening and follow-up care. The g…

This study is gathering tumor, blood, and plasma samples from over 1,000 people with certain cancers (ovarian, triple-negative breast, head and neck, cervical, vulva, and sarcoma). The goal is to find new biomarkers that link a tumor's genetic changes and the body's immune respon…

This study aims to understand why some ovarian cancer patients do not respond to platinum-based chemotherapy while others stay cancer-free for years. Researchers will compare genetic, clinical, and tissue samples from 55 patients treated at one center. The goal is to find differe…

This study takes tumor samples from people with breast, colorectal, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse-grown tumors to see which ones work best. The goal is to match each patient with a treatment that is most likely to s…

This study aims to develop and test a computer model that can predict whether a woman carries a harmful BRCA1 or BRCA2 gene mutation just by looking at ultrasound images of her healthy ovaries. Researchers will collect images from over 6,400 women across multiple hospitals and us…

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The main goal is to see how RAD301 moves through the body and how much radiation reaches orga…

This study looks at 50 women with ovarian cancer that came back quickly (within 6 months) to understand their survival patterns. Researchers will collect information like weight, age, tumor stage, and genetic details to improve how doctors categorize and manage these patients. No…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…

This study looks at whether a simple blood test can find genetic changes in tumor DNA that signal ovarian cancer is coming back. It involves 130 women with BRCA gene mutations who are taking a maintenance drug called Olaparib (with or without bevacizumab) after initial treatment.…

This study looks at the bacteria and natural chemicals in the vagina to see if they can help find ovarian cancer earlier. Healthy volunteers (people with ovaries but no cancer or genetic risk) will provide vaginal swabs and stool samples. Their samples will be compared to those f…

This study looks at whether watching a video before genetic testing helps people with certain cancers (like breast, ovarian, or prostate cancer) understand their hereditary cancer risk. About 1,020 adults who have or had cancer will watch an educational video and then answer ques…

This study is looking at whether chemotherapy given before surgery can improve physical fitness and thinking skills in older adults with advanced ovarian or endometrial cancer. Researchers will measure changes in frailty (physical weakness) and cognitive function after 3-4 rounds…

This study aims to improve methods for collecting and processing blood samples that could one day help detect ovarian cancer earlier. Researchers will recruit 1,500 postmenopausal women in Australia to donate blood and provide health information. The main goal is to understand ho…